Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment

Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment

Background: Psoriasis vulgaris is a common chronic dermatological disease that has a negative impact on the psychological status and the social interaction of the patient. Objective: To correlate the quality of life and clinical severity of psoriasis vulgaris in patients using different types of tre...

Full description

Bibliographic Details
Main Authors:	Ali Al Raddadi, Abdulhadi Jfri, Sahal Samarghandi, Nesreen Matury, Taha Habibullah, Majed Alfarshoti, Ahmad Mahdi
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2016-01-01
Series:	Journal of Dermatology and Dermatologic Surgery
Subjects:	Psoriasis vulgaris Dermatology life quality index (DLQI) Psoriasis area and severity index (PASI)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352241015000456

Similar Items

Sex Differences in Dermatology Life Quality Index (DLQI) among Patients with Psoriasis
by: Mikkel Bak Jensen, et al.
Published: (2024-12-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Exploring the Correlation between the PASI and DLQI Scores in Psoriasis Treatment with Topical Ointments Containing <i>Rosa × damascena</i> Mill. Extract
by: Diana Ioana Gavra, et al.
Published: (2024-08-01)

Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
by: Julia-Tatjana Maul, et al.
Published: (2024-03-01)

PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis
by: A. A. Kubanov, et al.
Published: (2017-08-01)

PASI and PQOL-12 score in psoriasis : Is there any correlation?
by: Vikas Shankar, et al.
Published: (2011-01-01)

Application of Dermatology Life Quality Index‐Relevant (DLQI‐R) in patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab
by: Philip Laws, et al.
Published: (2023-12-01)

Pengaruh Suplementasi Vitamin D Terhadap Perubahan Skor Psoriasis Area and Severity Index (PASI) Pada Pasien Psoriasis: Studi Kasus Dengan Pendekatan Berbasis Bukti
by: Anni Rahmawati, et al.
Published: (2024-03-01)

Relationship of Staphylococcal Aureus Colonization with Severity of Psoriasis Vulgaris Disease According to PASI Score
by: A. Darjani, et al.
Published: (2014-01-01)

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients
by: Teodora-Larisa Timis, et al.
Published: (2023-05-01)

Quality of life in patients with mild plaque psoriasis
by: Xiaoyu QIU, et al.
Published: (2023-04-01)

Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy
by: Lyubomir A. Dourmishev, et al.
Published: (2020-03-01)

Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review
by: de Ruiter CC, et al.
Published: (2022-05-01)

Associations between body mass index and severity of psoriasis
by: Sobhan M, et al.
Published: (2017-11-01)

Comparison of Psoriasis Area and Severity Index (PASI) Scores in Patients Treated with Oral Methotrexate and A Combination of Oral Methotrexate and Narrow Band-Ultraviolet B (NB-UVB) Phototherapy
by: Ervina Rosmarwati, et al.
Published: (2022-11-01)

Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients
by: Maria-Lorena Mustață, et al.
Published: (2025-01-01)

Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China
by: Yang J, et al.
Published: (2023-02-01)

Association between the disease severity and quality of life of patients with psoriasis in a tertiary government hospital in the Philippines: A retrospective cross-sectional study
by: Arbie Sofia P. Merilleno, MD, et al.
Published: (2024-09-01)

Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics
by: Kowalewska B, et al.
Published: (2021-02-01)

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
by: April W. Armstrong, et al.
Published: (2024-09-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

QUALITY OF LIFE IN PATIENTS WITH PSORIASIS AT A TERTIARY CARE TEACHING HOSPITAL –A CROSS SECTIONAL STUDY
by: Preksha A Barot, et al.
Published: (2022-05-01)

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
by: Paulina Maravilla-Herrera, et al.
Published: (2023-01-01)

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study
by: Bernhard Korge, et al.
Published: (2024-06-01)

Role of GDF-15 as an inflammatory marker in patients with psoriasis vulgaris
by: Mustafa Kaan Taşolar, et al.
Published: (2021-12-01)

Validation and application of the Dermatology Life Quality Index score, a modification of the DLQI score, in psoriasis patients
by: Qin Zou, et al.
Published: (2024-06-01)

CLINICAL AND DEMOGRAPHIC PROFILE OF PATIENTS WITH PSORIASIS AND ITS EFFECT ON THE QUALITY OF LIFE USING DERMATOLOGY QUALITY OF LIFE INDEX: A CROSS SECTIONAL STUDY
by: Sadaf Rauf, et al.
Published: (2019-12-01)

Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in psoriasis area and severity index after eight weeks of treatment among patients with psoriasis: Findings from a prospective study
by: Yan Qiang*, et al.
Published: (2024-04-01)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023-03-01)

The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review
by: Osman A, et al.
Published: (2024-01-01)

Association between systemic immune-inflammation index and psoriasis: a population-based study
by: Xiya Zhao, et al.
Published: (2024-03-01)

Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece)
by: Dimitrios Rigopoulos, et al.
Published: (2025-12-01)

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)
by: Ramtin Lichtenberger, et al.
Published: (2025-02-01)

C-Reactive Protein in Various Degrees Severity of Psoriasis Vulgaris
by: Lita Setyowatie, et al.
Published: (2016-10-01)

Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice
by: Savannah D. Neu, et al.
Published: (2021-08-01)

Plasma homocysteine levels in patients with Psoriasis
by: Mousumi Das
Published: (2017-08-01)

Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
by: sana imran, et al.
Published: (2014-08-01)

Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
by: sana imran, et al.
Published: (2014-08-01)

Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
by: Sana Imran, et al.
Published: (2014-08-01)

Interobserver variation of psoriasis area and severity index in a clinical setting
by: Neema Sandra Dias, et al.
Published: (2020-01-01)